Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC 0142-0000-0002 in Moderately to Severely Active Crohn's Disease
NCT01203631Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2011
- Primary completion
- May 2013
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing NNC 0142-0000-0002 with Placebo (2 arms). Primary endpoint: Change in Crohn's Disease Activity Index at 4 weeks. Started Feb 2011; status: completed.
02
Drugs
NNC0142-0002
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT01203631.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01203631.